Trending...
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 217
- City of Spokane Staff on Hand at Disaster Assistance Center
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global recurrent glioblastoma multiforme treatment market is estimated to be valued at US$ 369.6 million in 2020 and is projected to exhibit a CAGR of 6.14% during the forecast period (2020-2027).
Key Trends and Analysis:
The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals. For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, 'Zirabev', in the U.S. for the treatment of recurrent glioblastoma multiforme. Zirabev acts as a substitute for Avastin and is priced at a WAC (Wholesale Acquisition Cost) of US$ 61.34 per 10 mg. The U.S. FDA approved this biosimilar in June 2019 for the treatment of recurrent glioblastoma multiforme, metastatic or recurrent NSCLC, recurrent/persistent or metastatic cervical cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma.
For instance, in November 2019, the U.S. FDA accepted Samsung's BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this will gets approval, thisen, the biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung's partner on its biosimilar of infliximab – RenflexisKey industry players are implementing research collaborations and joint ventures to discover & develop novel drugs, which is significantly driving growth of the market. For instance, in October 2019, UCLA and Advaxix jointly entered into an agreement for research on GBM immunotherapy products. The companies aimed to conduct preclinical studies evaluating the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
More on Washingtoner
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682
Key Market Takeaways:
The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences, in order to conduct VAL-083's phase III trials for the treatment of recurrent glioblastoma multiforme.
North America recurrent glioblastoma multiforme treatment market is expected to be the most lucrative region during the forecast period, owing to increasing investments in R&D activities and FDA approvals for clinical trials in this region. For instance, in October 2019, Denovo Biopharma was granted the FDA approval for its phase IIb clinical trial assessing an analytical permutation therapy for the treatment of newly diagnosed GBM patients.
Competitive Landscape:
Key players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., GW Pharmaceuticals Plc, AstraZeneca, ImmunoCellular Therapeutics, Ltd., F. Hoffman-La Roche, Ltd., Genzyme Corporation, Pfizer, Inc., ERC Belgium SA, Merck & Co., Inc., GenSpera, Inc., Vascular Biogeneics, EnGeneIC Ltd., AngioChem, Inc., Boehringer Ingelheim GmbH, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Boston Biomedical, Inc., Eisai, Cantex Pharmaceuticals, Inc., Coherus BioSciences, Inc., Celldex Therapeutics, Inc., and Cavion LLC
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/682
More on Washingtoner
Market Segmentation:
Related Market Intelligence Reports:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals. For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, 'Zirabev', in the U.S. for the treatment of recurrent glioblastoma multiforme. Zirabev acts as a substitute for Avastin and is priced at a WAC (Wholesale Acquisition Cost) of US$ 61.34 per 10 mg. The U.S. FDA approved this biosimilar in June 2019 for the treatment of recurrent glioblastoma multiforme, metastatic or recurrent NSCLC, recurrent/persistent or metastatic cervical cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma.
For instance, in November 2019, the U.S. FDA accepted Samsung's BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this will gets approval, thisen, the biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung's partner on its biosimilar of infliximab – RenflexisKey industry players are implementing research collaborations and joint ventures to discover & develop novel drugs, which is significantly driving growth of the market. For instance, in October 2019, UCLA and Advaxix jointly entered into an agreement for research on GBM immunotherapy products. The companies aimed to conduct preclinical studies evaluating the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
More on Washingtoner
- 5.6 Million EUR in Q1 Project Awards for Integrated IoT Solutions / Data Analytics Subsidiary of Smart City Developer: Affluence (Stock Symbol: AFFU)
- Merger Advancement For Embodied AI Co in Robotic Systems Serving High Value Hospitality, Gaming & Real Estate Sectors: MBody AI Corp. (NAS DAQ: MBAI)
- Hollywood In Pixels Announces Honorees for The 9th Silver PIXel Awards
- New Research Finds a Good Deal Is All It Takes to Get Americans Booking a Last-Minute Vacation — and Most Already Have One on Their Mind
- GitKraken Introduces GitLens 19, Bringing Human and AI Workflows Together in One Workbench
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682
Key Market Takeaways:
The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences, in order to conduct VAL-083's phase III trials for the treatment of recurrent glioblastoma multiforme.
North America recurrent glioblastoma multiforme treatment market is expected to be the most lucrative region during the forecast period, owing to increasing investments in R&D activities and FDA approvals for clinical trials in this region. For instance, in October 2019, Denovo Biopharma was granted the FDA approval for its phase IIb clinical trial assessing an analytical permutation therapy for the treatment of newly diagnosed GBM patients.
Competitive Landscape:
Key players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., GW Pharmaceuticals Plc, AstraZeneca, ImmunoCellular Therapeutics, Ltd., F. Hoffman-La Roche, Ltd., Genzyme Corporation, Pfizer, Inc., ERC Belgium SA, Merck & Co., Inc., GenSpera, Inc., Vascular Biogeneics, EnGeneIC Ltd., AngioChem, Inc., Boehringer Ingelheim GmbH, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Boston Biomedical, Inc., Eisai, Cantex Pharmaceuticals, Inc., Coherus BioSciences, Inc., Celldex Therapeutics, Inc., and Cavion LLC
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/682
More on Washingtoner
- LĪNA Universal Balm Nominated for "Best Clean Skincare Product" at CertClean Beauty Awards
- Spokane: SPD Arrest Level III Registered Sex Offender for Failure to Register
- SPD Detectives Investigating Suspicious Deaths in Northeast Spokane
- Bronze Stevie Award Recognizes Satyadhar Joshi for AI Research and Public Policy Engagement
- synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
Market Segmentation:
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Region:
- North Africa
- Central Africa
- South Africa
- By Region:
- North America
Related Market Intelligence Reports:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Crownlight Strategies® Announces Federal Trademark Registration
- Spokane: PPE Available to Those Returning Home After New Evacuation Downgrades
- Spokane Police Respond to a Vehicle vs. Pedestrian
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success
- Tacoma City Council Set to Join Pierce County's Efforts to Launch Unified Regional Approach to Reduce Homelessness
- Igbozue Connecticut USA Celebrates 2026 Summer Family Picnic
- KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
- Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
- OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
- Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
- Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
- Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
- ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
- ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
- The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
- PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results